HOME >> MEDICINE >> NEWS
Acrux reports progress in development of Testosterone MD-Lotion(R) for men

Acrux Limited (ASX: ACR), the Australian pharmaceutical company which specialises in administering drugs through the skin, today announced positive results from two more clinical studies of its Testosterone MD-Lotion treatment for testosterone deficiency in men, which is associated with a number of symptoms including lethargy, depression and reduced libido. Both studies were conducted at the Centre for Clinical Studies, Melbourne, with Professor Susan Davis supervising as Principal Investigator.

The studies compared blood levels of testosterone in healthy volunteers. The aim of the first study was to compare two different formulations of Testosterone MD Lotion, and the aim of the second study was to compare two different application sites.

The results of the first study showed that both formulations provided similar blood levels, providing options for continued development of either formulation. In the second study, there was a significant difference in absorption between the two different application sites, providing important information for the design of the remaining clinical studies in men.

In both studies, the lotion was well tolerated, with no application site reactions noted, and no serious adverse events recorded. Full details of the studies are presented in Appendix 1.

Acrux's development of Testosterone MD Lotion is continuing, with further studies to commence shortly to confirm the doses required to maintain testosterone blood levels in the target range for effective treatment.

Acrux CEO and Managing Director, Dr Igor Gonda said: "We believe our fast drying, no-touch metered dose lotion has significant competitive advantage over the existing products in this growing market. The remaining trials suit our expertise and require moderate investment, so in line with our financial plans we intend to complete them ourselves before choosing the best option for sales and marketing".

The remaining development prog
'"/>

Contact: Igor Gonda
61-383-790-100
Research Australia
7-Sep-2005


Page: 1 2

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. Acrux and Oreganon further expand their collaboration
3. Acrux granted first grant in Europe, triggering payment from Lilly
4. Acrux patent portfolio advances in USA
5. Acrux acquires rights to commercialise worlds first contraceptive spray
6. Four new us patents granted to Acrux for transdermal drug delivery
7. New study reports hotel guests at risk from carbon monoxide poisoning
8. MIT reports key pathway in synaptic plasticity
9. ENDEAVOR III Trial reports key findings on new-generation stent
10. New study reports improved treatment and reduced mortality for patients with heart failure
11. Study reports changing to a low-fat diet can induce stress

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
Cached News: